A new report by FutureWise Research highlights a powerful trend in modern medicine: as awareness and innovation rise, hope ...

Carcinoid tumor of midgut origin with large segment ... This device disrupts the liver parenchyma at the resection site, allowing ligation and division of the vessels and bile duct branches.

Q1 2025 Earnings Call Transcript May 8, 2025 Crinetics Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.04 EPS, expectations were $-0.99. Operator: And the call will begin ...

Karla Flores was diagnosed with a rare brain tumor. An misplaced MRI found a second, nearly inoperable, tumor on her spine.

Abdominal CT showed multiple hepatic masses, and needle biopsy yielded tissue consistent with a neuroendocrine tumor of the carcinoid type. Octreotide imaging localized the primary tumor to the ...

Today some of the most aggressive solid tumor cancers remain stubbornly resistant to treatment. There are many reasons why ...

START and OneOncology launch 3 new early-phase trial sites, expanding access to new cancer research in community oncology ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Clinical and molecular determinants of survival in pancreatic neuroendocrine tumors: A comprehensive analysis from SEER and TCGA databases.

"I have no idea how many people in my neighborhood died from cancer," said New Monrovia resident Leonardo Lee.

Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies ...